




Critical Care - Infection Diseases Network

2022 Inaugural Virtual Symposium

Life-Threatening Infections and COVID-19 Disease

February 24 - 25, 2022



ABOUT

This academic program was developed by the members of the Critical Care – Infectious Diseases Network, a group of clinicians and researchers trained in critical care medicine and infectious diseases/microbiology. This program is designed for specialists in internal medicine or surgery with an interest in severe and life-threatening infections and infections occurring in the critically ill. Critical care physicians, hospitalists and infectious diseases physicians in particular will find the material covered important in improving their clinical practice. Key topics to be discussed include optimization of antimicrobial therapy, newly introduced antimicrobials, resistance trends and, of course, the latest in COVID-19 data.

Learning Objectives

At the end of the conference, participants will be able to:

- understand advanced concepts in COVID diagnostics and therapeutics;
- appreciate how to optimize dosing to take advantage of PK principles in management of life-threatening infections;
- recognize the role of adjunctive and novel diagnostic techniques for serious infections;
- evaluate the relative importance of antimicrobial resistance with respect to therapy.

Please Note

- All times listed in the program are in Eastern Time.
- A minimum of 25% of each session will be dedicated to participant interaction.



Thursday, February 24, 2022

8:55 a.m. EST		Delegates – Virtual Check-In
9:00 a.m. - 9:15 a.m.	LINE 1	Opening Address Anand Kumar and CCIDN Organizing Committee with special address by Dennis Maki and Bruce Light
Concurrent Sessions: Block 1		
9:20 a.m. - 9:55 a.m.	LINE 1	What's New in Antimicrobials Used in the ICU? Wendy Sligl
	LINE 2	Antimicrobial Stewardship in the Face of Suspected Sepsis Sameer Kadri
Concurrent Sessions: Block 2		
10:00 a.m. - 10:35 a.m.	LINE 1	What's New in Antimicrobial Resistance in the ICU? Andre Kalil
	LINE 2	The Modern Approach to the Diagnosis of Fungal Sepsis Coleman Rotstein
10:35 a.m. - 10:45 a.m.		Break
Concurrent Sessions: Block 3		
10:45 a.m. - 11:20 a.m.	LINE 1	Options for Difficult-To-Treat Gram-Negative Infections – What to Choose and When Matteo Bassetti
	LINE 2	Treating Invasive Candida Sepsis Eric Bow
Concurrent Sessions: Block 4		
11:25 a.m. – 12:00 p.m.	LINE 1	Options for MRSA Infections – What to Choose and When Salman Qureshi
	LINE 2	Considerations for the Treatment of HAP/VAP in Patients at High Risk of Mortality Ignacio Martin-Loeches
12:00 a.m. - 12:30 p.m.		Lunch
Concurrent Sessions: Block 5		
12:30 p.m.- 1:05 p.m.	LINE 1	Vancomycin AUC for Serious MSRA Infections Tom Lodise
	LINE 2	Initiating, Escalating, De-escalating and Stopping Antibiotics in the ICU Patient Nick Daneman
Concurrent Sessions: Block 6		
1:10 p.m. - 1:45 p.m.	LINE 1	CAP Empiric Therapy and De-escalation Strategies Srinivas Murthy
	LINE 2	Use of Immunoglobulin Therapy for Infection/Sepsis in the ICU Evangelos Giamarellos-Bourboulis
Concurrent Sessions: Block 7		
1:50 p.m. - 2:25 p.m.	LINE 1	HAP Empiric Therapy and De-escalation Strategies Andre Kalil
	LINE 2	New Perspectives on Severe Influenza and Non-influenza Respiratory Virus Infections Nelson Lee

2:25 p.m. - 2:35 p.m.		Break
Concurrent Sessions: Block 8		
2:35 p.m. - 3:10 p.m.	LINE 1	Prolonged and Extended β -lactam Infusion for Critical Infections in ICU Jason Roberts
	LINE 2	How to Use Procalcitonin in the ICU Gloria Vazquez-Grande
Concurrent Sessions: Block 9		
3:15 p.m. – 3:50 p.m.	LINE 1	Therapeutic Drug Monitoring in the ICU Jason Roberts
	LINE 2	Antimicrobials in Sepsis and Septic Shock: How Fast is Too Fast? Chris Seymour
Concurrent Sessions: Block 10		
3:55 p.m. – 4:30 p.m.	LINE 1	Emerging Rapid Microbiologic Molecular Diagnostic Technologies Donna Wolk and Shravan Kethireddy
	LINE 2	Antimicrobials In Critical Illness: How Fast Is Fast Enough? Mike Klompas
Concurrent Sessions: Block 11		
4:35 p.m. - 5:10 p.m.	LINE 1	Clinical Management Guidelines for Pandemics: Are They Worth the Effort? Henry Masur
	LINE 2	Primer on Coronavirus Infections in Humans Sylvain Lothar

Friday, February 25, 2022

8:20 a.m. – 8:25 a.m. EST	Delegates – Virtual Check-In
8:25 a.m. – 8:30 a.m.	Welcome Anand Kumar
8:30 a.m. – 8:50 p.m.	SARS Robert Fowler
8:50 p.m. – 9:10 a.m.	MERS Yaseen Arabi
9:10 a.m. - 9:40 a.m.	Through a Glass Darkly: Measuring Prognosis in COVID-19 Ryan Maves
9:40 a.m. - 10:10 a.m.	COVID-19: The Pediatric Perspective Angela Bates
10:10 a.m. - 10:40 a.m.	What We Know About Genetic, Clinical and Racial Predisposition Ken Baillie
10:40 a.m. - 11:00 a.m.	Break
11:00 a.m. - 11:30 a.m.	What You Need to Know About the Diagnosis of Severe COVID-19 Duane Funk
11:30 a.m. - 12:00 p.m.	Respiratory Injury and Mechanical Support Salman Qureshi

12:00 p.m. - 1:00 p.m.	Lunch
1:00 p.m. - 1:30 p.m.	The Nature of Extra-Pulmonary Organ Injury and Support Ken Wood
1:30 p.m. - 2:00 p.m.	Co-infections and Complications Josh Douglas
2:00 p.m. - 2:30 p.m.	Heparin Therapy of COVID-19...Theory and Data Ryan Zarychanski
2:30 p.m. - 2:45 p.m.	Break
2:45 p.m. - 3:15p.m.	Inpatient Passive Immune Therapy for COVID-19 John Beigel
3:15 p.m. - 3:45 p.m.	Immune Modulation Therapy of Severe COVID-19 Srinivas Murthy
3:45 p.m. - 4:15 p.m.	Inpatient Antiviral Therapy for COVID-19 John Beigel
4:15 p.m. – 4:55 p.m.	COVID-19: Where We’ve Been and Where We’re Going Amesh Adalja
4:55 p.m. – 5:00 p.m.	Closing Remarks

Sponsors

This program has received an educational grant or in-kind support from:

Gold

Merck & Co.
Paladin Labs Inc.

Silver

Gilead Sciences Inc.

Bronze

GlaxoSmithKline
Hoffman-La Roche Ltd.
Pfizer Inc.
Sandoz Canada Inc.